Qrons Inc.

Qrons, Inc. (OTC: QRON) is a biopharmaceutical development company focused on the development of innovative therapeutic approaches for traumatic brain injury (TBI) using biodegradable scaffold technology designed to support neural tissue repair and regeneration following brain injury. According to its website at qrons.com, the company's research platform is focused on the development of injectable biodegradable polymer scaffolds that can be delivered directly to damaged brain tissue following traumatic brain injury, providing structural support for neural repair processes while gradually degrading as the tissue heals. Qrons' scaffolding approach to TBI therapy addresses the complex challenge of providing the structural and biochemical environment required for neural repair in the injured brain without implanting permanent devices that could create long-term complications.

Qrons' biodegradable scaffold technology, described at qrons.com, involves the development of polymer materials with the biocompatibility, mechanical properties, and degradation characteristics required to function as temporary scaffolds in the injured brain — supporting tissue repair without triggering significant inflammatory responses or interfering with the brain's natural healing processes as the scaffold gradually dissolves. The company's research programs investigate both the materials science of biodegradable scaffold formulation and the neurobiological interactions between scaffold materials and brain tissue, seeking to develop scaffold systems that actively promote neural repair through the combined effects of structural support and potentially bioactive elements incorporated into the scaffold material. TBI affects millions of Americans annually from sports injuries, falls, motor vehicle accidents, and military combat, with limited pharmacological treatment options for the neural repair process.

Qrons is a pre-clinical stage development company pursuing the foundational research required to advance its biodegradable brain scaffold concept toward preclinical efficacy and safety studies that could support eventual human clinical trials. According to qrons.com, the company's development activities are at an early stage, with ongoing research focused on characterizing and optimizing scaffold materials and evaluating their biological performance in preclinical models of traumatic brain injury. Qrons' combination of biodegradable neural scaffold concept, traumatic brain injury therapeutic focus, early-stage development positioning, OTC-listed public company structure, and mission to develop novel approaches to neural repair reflects its participation in the scientifically challenging and medically important area of TBI treatment development.